 JERSEY CITY, N.J., June 23, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that it will present a commercial launch update for its recently FDA-approved drug, BREXAFEMME ibrexafungerp tablets. BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis VVC, or vaginal yeast infections. It is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp. 